Literature DB >> 26472266

Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.

Liyan Cao1, Yunjie Zhang1, Zhanzhao Fu1, Lixin Dong1, Sen Yang1, Wei Meng2, Yiyang Li1, Wenchao Zhang1, Jialing Zhang1, Changjun Zheng1, He Zhu1, Limei Fan1.   

Abstract

AIM: We investigated whether plasma levels of lysophosphatidic acid (LPA) could serve as a diagnostic indicator for assessing disease progression in ovarian cancer (OC) patients.
MATERIAL AND METHODS: In this study, we enrolled 98 patients with OC, 70 patients with benign ovarian tumors and 75 healthy controls. Plasma levels of LPA and cancer antigen 125 (CA-125) were measured in all study subjects. The diagnostic values of LPA and CA-125 plasma levels were evaluated and an updated meta-analysis was performed to examine the association between LPA plasma levels and OC progression. Statistical analyses were performed with SPSS 18.0 and R 3.1.0 software.
RESULTS: In our case-control study, OC patients showed significantly higher plasma LPA levels compared to patients with benign tumors and healthy controls (all P < 0.05). Plasma LPA levels exhibited higher diagnostic sensitivity (P = 0.008) and specificity (P = 0.042) in detecting OC, compared to an established marker, CA-125. Notably, the sensitivity for early stage OC was significantly higher for plasma LPA levels in comparison to CA-125 (P < 0.05). Consistent with this, the area under the receiver-operator curve was greater for LPA (0.899) in comparison to that for CA-125 (0.751). Further, meta-analysis showed that plasma LPA levels were significantly higher in OC patients compared to patients with benign tumors or healthy controls (all P < 0.05).
CONCLUSION: Plasma LPA levels are elevated in OC patients and correlate with disease progression. Further, LPA shows higher sensitivity and specificity in OC diagnosis, compared to CA-125, especially in early stage OC.
© 2015 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  bioactive phospholipid; differential diagnosis; lysophosphatidic acid; ovarian cancer; sensitivity and specificity

Mesh:

Substances:

Year:  2015        PMID: 26472266     DOI: 10.1111/jog.12806

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  8 in total

1.  Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.

Authors:  Petra C Buchanan; Kristin L M Boylan; Bruce Walcheck; Rachel Heinze; Melissa A Geller; Peter A Argenta; Amy P N Skubitz
Journal:  J Biol Chem       Date:  2017-02-23       Impact factor: 5.157

2.  Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.

Authors:  Hiroshi Deguchi; Darlene J Elias; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2017-06-20

Review 3.  Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1.

Authors:  Divij Mathew; Raul M Torres
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

Review 4.  Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies.

Authors:  Luiz Henrique Medeiros Geraldo; Tânia Cristina Leite de Sampaio Spohr; Rackele Ferreira do Amaral; Anna Carolina Carvalho da Fonseca; Celina Garcia; Fabio de Almeida Mendes; Catarina Freitas; Marcos Fabio dosSantos; Flavia Regina Souza Lima
Journal:  Signal Transduct Target Ther       Date:  2021-02-01

5.  The incidence and risk of osteoporosis in patients with anxiety disorder: A Population-based retrospective cohort study.

Authors:  Chen Hong-Jhe; Kuo Chin-Yuan; Tu Ming-Shium; Wang Fu-Wei; Chen Ru-Yih; Hsueh Kuang-Chieh; Pan Hsiang-Ju; Chou Ming-Yueh; Chen Pan-Ming; Pan Chih-Chuan
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

6.  Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy.

Authors:  LeAnn C Rogers; Ryan R Davis; Naveen Said; Thomas Hollis; Larry W Daniel
Journal:  Redox Biol       Date:  2018-01-04       Impact factor: 11.799

7.  Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry.

Authors:  Lászó Márk; Zsolt Balogi; Janos Schmidt; Béla Kajtár; Kata Juhász; Mária Péter; Tamás Járai; András Burián; László Kereskai; Imre Gerlinger; Tamás Tornóczki; Gábor Balogh; László Vígh
Journal:  Oncotarget       Date:  2020-07-14

8.  Profiling lysophosphatidic acid levels in plasma from head and neck cancer patients.

Authors:  Mariati Abdul Rahman; Didi Erwandi Mohamad Haron; Robert J Hollows; Zuleen Delina Fasya Abdul Ghani; Mustafa Ali Mohd; Wen Lin Chai; Ching Ching Ng; Munn Sann Lye; Saiful Anuar Karsani; Lee Fah Yap; Ian C Paterson
Journal:  PeerJ       Date:  2020-06-05       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.